Malaysia Introduces Reliance and Priority Review Mechanisms for Additional Drug Indication Applications

Malaysia’s National Pharmaceutical Regulatory Agency (NPRA) has introduced new regulatory mechanisms intended to streamline the review of additional indication applications (AI) for registered innovator products.

The new framework was issued through a Drug Control Authority (DCA) Directive dated 15 January 2026 and implemented through updates to the Drug Registration Guidance Document (DRGD), 3rd Edition, 11th Revision (January 2026).

The directive establishes two regulatory mechanisms:

• Reliance-based review pathways
• Priority Review for specific oncology additional indication applications

These changes aim to improve regulatory efficiency by leveraging prior assessments performed by trusted international regulators while maintaining NPRA’s authority over the final regulatory decision.

Reliance Mechanism for Additional Indication Applications

The new Reliance mechanism allows the National Pharmaceutical Regulatory Agency (NPRA) to leverage prior scientific assessments conducted by trusted regulatory authorities when evaluating applications for additional indications of already registered innovator products.

Under this framework, NPRA may rely on the assessment and approval decisions made by Drug Control Authority (DCA) reference agencies, provided that the indication, dosage regimen, patient population, and conditions of use remain consistent with the reference approval.

While the reliance approach allows NPRA to utilize existing regulatory evaluations, the agency retains full authority over the final regulatory decision for Malaysia.

Eligible Reference Authorities

The reliance pathway applies to additional indications approved by Drug Control Authority (DCA) reference agencies, including:

• U.S. Food and Drug Administration (FDA)
• European Medicines Agency (EMA)
• Medicines and Healthcare products Regulatory Agency (MHRA)
• Swedish Medical Products Agency (MPA)
• French National Agency for the Safety of Medicines and Health Products (ANSM)
• Therapeutic Goods Administration (TGA) Australia
• Health Canada
• Pharmaceuticals and Medical Devices Agency (PMDA)
• Swissmedic

These agencies are recognized by NPRA as trusted regulatory authorities whose scientific assessments may be considered during the Malaysian review process.

Review Pathways for Additional Indications

Under the updated framework, NPRA has established four evaluation routes for additional indication (AI) applications for registered innovator products.

AI Standard Full Evaluation

This pathway applies where the additional indication has been approved by one DCA reference agency.

NPRA conducts a full scientific review of the submitted data package.

Target evaluation timeline: 180 working days (excluding screening and applicant response time).

AI Standard Verification

This pathway applies when the additional indication has been approved by two or more DCA reference agencies.

NPRA performs a verification review based on approvals from reference authorities and the submitted documentation.

Target evaluation timeline: 150 working days.

AI Reliance Full Evaluation

This pathway allows NPRA to rely on the assessment report of a reference agency when conducting its review.

Eligibility criteria generally include:

• Approval of the additional indication by one DCA reference agency
• Approval obtained within three years prior to submission
• Consistency of indication, dosage, patient population, and conditions of use with the reference approval
• No rejection, withdrawal, or unresolved safety or efficacy concerns in other jurisdictions

Target evaluation timeline: 90 working days.

AI Reliance Verification

This pathway applies when the additional indication has been approved by two or more DCA reference agencies.

NPRA conducts a verification review while relying on prior assessments performed by those authorities.

Target evaluation timeline: 90 working days.

Priority Review Mechanism

The directive also introduces a Priority Review pathway designed to accelerate regulatory evaluation for certain additional indication applications.

Priority Review eligibility is limited to oncology additional indication applications supported by Phase III global multicenter pivotal clinical trials conducted in Malaysia, where Malaysian study sites represent at least 5% of randomized subjects.

For applications meeting these criteria, evaluation timelines may be shortened.

Priority Review timelines:

Review PathwayTimelinesAI Standard Full Evaluation120 working daysAI Standard Verification100 working days

Requests for Priority Review must be submitted through QUEST3+ at the time of application and supported by a formal cover letter.

This pathway is not a general accelerated route for high-impact therapies. Instead, it applies specifically to oncology additional indications supported by qualifying Phase III global multicenter trials conducted in Malaysia meeting the defined Malaysian participation threshold.

Documentation Requirements

Applicants must provide supporting documentation demonstrating the regulatory status and scientific basis for the additional indication.

Typical submission elements include:

• Approval status of the additional indication in reference jurisdictions
• Approved package inserts from reference authorities
• Proposed Malaysian package inserts
• Clinical overview
• Clinical efficacy and safety summaries
• Study synopses and clinical study reports
• Relevant published literature, where applicable
• Latest Periodic Benefit-Risk Evaluation Report (PBRER)

For reliance submissions, NPRA may additionally require:

• Unredacted assessment reports from the reference agency
• Regulatory correspondence or questions and responses related to the assessment
• A declaration confirming authenticity of the submitted reports
• The completed AI Reliance checklist

Regulatory Considerations

Several operational considerations should be taken into account when preparing submissions under the new framework:

• NPRA may reclassify an application from a reliance pathway to a standard evaluation if reliance criteria are not met.
• Multiple additional indications may be submitted in a single application only if supported by a single assessment report from the reference authority.
• Applications undergo a screening stage of approximately 30 working days before evaluation begins.

Malaysia’s Regulatory Framework Moves Closer to Global Reliance Practices

Beyond the immediate procedural changes, the directive reflects Malaysia’s broader shift toward reliance-based regulatory review, allowing NPRA to leverage prior assessments from DCA reference agencies while retaining authority over the local decision.

For international pharmaceutical companies, this development highlights the growing role of cross-jurisdiction regulatory reliance, where approvals in one market may support regulatory opportunities in another. Companies pursuing drug registration or additional indications for innovative medicines in Malaysia should therefore closely monitor how the National Pharmaceutical Regulatory Agency implements the new mechanism in practice.

For support navigating evolving regulatory pathways across Asia, companies can contact Cisema. With more than 20 years of experience supporting international manufacturers, Cisema helps companies translate regulatory developments into clear strategies for compliant and efficient market entry across the Asia Pacific region.

References

• Read the official directive, “Directive on the Implementation of Reliance and Priority Review Mechanisms for Additional Indication Applications of Registered Innovator Products”
• Consult the “Drug Registration Guidance Document (DRGD), Third Edition, 11th Revision, January 2026”
• See also “Drug Registration Guidance Document (DRGD), Third Edition, 11th Revision, January 2026 – Appendix 12: Priority Review”